A:

In 1982,

The U.S. Food and Drug Administration (FDA) recognized the lack of incentive for pharmaceutical companies to develop cures for rare diseases and established the Office of Orphan Product Development. This branch of the FDA provides incentives to companies that work toward curing rare diseases by exercising the rights given to them under the Orphan Drug Act of January 1983. One type of incentive is the orphan drug status, which provides tax reductions and the exclusive right to develop the cure for a specific condition for a period of seven years to companies attempting to cure rare diseases.

Developing drugs to treat the vast number of diseases in the world is a line of business that can lead to massive fortunes, but unfortunately not all developed drugs become the golden ticket. In the world pharmaceuticals, the largest amount of money can be made by developing drugs that become the standard for curing common diseases.

From a business perspective, having a large market ensures that a company can quickly recuperate the cost of development and can also realize the largest possible gain. For this reason, there is little incentive for pharmaceutical companies to develop cures for rare diseases - those that affect fewer than 200,000 people in the United States - because the small market and high cost associated with finding these types of cures discourages these companies from entering this market.

For related reading, check out Measuring The Medicine Makers.

RELATED FAQS

  1. What does it mean when a company in the drug sector has orphan drugs?

    Understand what it means when a company in the pharmaceutical industry has drugs within its portfolio that are designated ...
  2. What impact did the Sarbanes-Oxley Act have on corporate governance in the United ...

    Learn the effects the Sarbanes-Oxley Act has on corporate governance in the United States, including strict disclosures, ...
  3. Who regulates the various types of exchange traded funds (ETFs)?

    Discover who regulates various types of exchange-traded funds. The share of investment capital going towards ETFs continues ...
  4. Do small banks ever act as custodians?

    Examine why smaller custodian banks struggle to compete with larger custodian banks because of economies of scale and existing ...
RELATED TERMS
  1. Assigned Risk

    A risk that an insurance company is required to provide coverage ...
  2. NEXUS

    A Trusted Traveler Program that allows pre-screened U.S. and ...
  3. Global Entry

    A U.S. program giving pre-approved travelers a faster Customs ...
  4. SENTRI

    This U.S. program grants pre-approved travelers access to a faster ...
  5. Separation Of Powers

    An organizational structure in which responsibilities, authorities, ...
  6. Nordic Model

    The social welfare and economic systems adopted by Nordic countries.

You May Also Like

Related Articles
  1. Investing Basics

    What does it mean when a company in ...

  2. Taxes

    Corporate Tax Rates: The Highs and the ...

  3. Investing News

    A New Corporate Governance Initiative ...

  4. Economics

    The New Global Banking Regulations To ...

  5. Stock Analysis

    Zynga's New Venture Is A Major Gamble

Trading Center